These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 11828751)
1. [Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma]. Kato H; Nagata O; Yamazaki M; Suzuki T; Nakano Y Yakugaku Zasshi; 2002 Jan; 122(1):57-69. PubMed ID: 11828751 [TBL] [Abstract][Full Text] [Related]
2. Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy. Burioka N; Miyata M; Endo M; Fukuoka Y; Suyama H; Nakazaki H; Igawa K; Shimizu E Chronobiol Int; 2005; 22(2):383-90. PubMed ID: 16021849 [TBL] [Abstract][Full Text] [Related]
3. Transdermal tulobuterol patch, a long-actingβ(2)-agonist. Tamura G; Ichinose M; Fukuchi Y; Miyamoto T Allergol Int; 2012 Jun; 61(2):219-29. PubMed ID: 22270072 [TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity]. Horiguchi T; Kondo R; Miyazaki J; Torigoe H; Tachikawa S Nihon Kokyuki Gakkai Zasshi; 2004 Feb; 42(2):132-7. PubMed ID: 15007912 [TBL] [Abstract][Full Text] [Related]
5. Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. Kume H; Kondo M; Ito Y; Suzuki R; Yamaki K; Takagi K Clin Exp Pharmacol Physiol; 2002 Dec; 29(12):1076-83. PubMed ID: 12390295 [TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Uematsu T; Nakano M; Kosuge K; Kanamaru M; Nakashima M Eur J Clin Pharmacol; 1993; 44(4):361-4. PubMed ID: 8099880 [TBL] [Abstract][Full Text] [Related]
7. Skin permeability of tulobuterol in two transdermal formulations and their followability. Takizawa Y; Goto T; Sato S; Ohmori N; Mori K; Shimada Y; Chen K; Miyagi T; Fukai F Drug Discov Ther; 2017 Nov; 11(5):253-258. PubMed ID: 29021505 [TBL] [Abstract][Full Text] [Related]
8. Tulobuterol in childhood asthma: single dose ranging and repeated oral dose comparative studies. Javier MA; Noche ML J Int Med Res; 1986; 14(5):228-35. PubMed ID: 2876923 [TBL] [Abstract][Full Text] [Related]
9. Effects of transdermal tulobuterol in pediatric asthma patients on long-term leukotriene receptor antagonist therapy: results of a randomized, open-label, multicenter clinical trial in Japanese children aged 4-12 years. Katsunuma T; Fujisawa T; Nagao M; Akasawa A; Nomura I; Yamaoka A; Kondo H; Masuda K; Yamaguchi K; Terada A; Ikeda M; Nishioka K; Adachi Y; Kurihara K Allergol Int; 2013 Mar; 62(1):37-43. PubMed ID: 23000726 [TBL] [Abstract][Full Text] [Related]
11. The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma. Yoshihara S; Yamada Y; Abe T; Arisaka O Ann Allergy Asthma Immunol; 2006 Jun; 96(6):879-80. PubMed ID: 16802779 [No Abstract] [Full Text] [Related]
12. Transdermal treatment with tulobuterol increases isometric contractile properties of diaphragm muscle in mice. Shindoh C; Tsushima R; Shindoh Y; Tamura G Tohoku J Exp Med; 2007 Jul; 212(3):309-17. PubMed ID: 17592218 [TBL] [Abstract][Full Text] [Related]
13. Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis. Shindoh C; Murakami Y; Shishido R; Sasaki K; Nishio T; Miura M Tohoku J Exp Med; 2009 Aug; 218(4):271-8. PubMed ID: 19638730 [TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma. Horiguchi T; Kondo R; Miyazaki J; Fukumokto K; Torigoe H Arzneimittelforschung; 2004; 54(5):280-5. PubMed ID: 15212190 [TBL] [Abstract][Full Text] [Related]
15. Prolonged treatment with oral and inhaled tulobuterol does not induce airways tachyphlaxis. Patel KR Lung; 1990; 168 Suppl():210-8. PubMed ID: 1974679 [TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of marketed transdermal delivery systems for tulobuterol. Tojo K; Hikima T Biol Pharm Bull; 2007 Aug; 30(8):1576-9. PubMed ID: 17666825 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. Iikura Y; Uchiyama H; Akimoto K; Ebisawa M; Sakaguchi N; Tsubaki T; Ishizu H; Kabayama H; Yagi K; Miura K Ann Allergy Asthma Immunol; 1995 Feb; 74(2):147-51. PubMed ID: 7697473 [TBL] [Abstract][Full Text] [Related]
18. Bioequivalence assessment of tulobuterol transdermal delivery system in healthy subjects . Park SI; Kim BH Int J Clin Pharmacol Ther; 2018 Aug; 56(8):381-386. PubMed ID: 29932416 [TBL] [Abstract][Full Text] [Related]
19. Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. Kobayashi Y; Yasuba H; Kudou M; Kita H J Asthma; 2007 Mar; 44(2):77-81. PubMed ID: 17454319 [TBL] [Abstract][Full Text] [Related]
20. [Effect of a patch formulation of tulobuterol on cough scores and PEF in patients with cough variant asthma]. Fujimori K; Suzuki E; Gejyo F Arerugi; 2000 Aug; 49(8):658-61. PubMed ID: 11021018 [No Abstract] [Full Text] [Related] [Next] [New Search]